Human mesenchymal stem cells increase anti-oxidant defences in cells derived from patients with friedreich's ataxia

Cerebellum

Volumn 11, Issue 4, 2012, Pages 861-871

  Dey, Rimi ^a   Kemp, Kevin ^a,b   Gray, Elizabeth ^a   Rice, Claire ^a   Scolding, Neil ^a   Wilkins, Alastair ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Frataxin; Friedreich's ataxia; Mesenchymal stem cells; Oxidative stress; Superoxide dismutase

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; FRATAXIN; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; FIBROBLAST; FRIEDREICH ATAXIA; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FIBROBLASTS; FRIEDREICH ATAXIA; HUMANS; HYDROGEN PEROXIDE; IRON; IRON-BINDING PROTEINS; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS;

EID: 84870419209     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-012-0406-2     Document Type: Article

References (56)

1. Alper G, Narayanan V. Friedreich's ataxia. Pediatr Neurol. 2003;28:335-41. (Pubitemid 36876131)
2. Durr A. Friedreich's ataxia: treatment within reach. Lancet Neurol. 2002;1:370-4. (Pubitemid 37159162)
3. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256 Suppl 1:3-8.
4. Rufini A, Fortuni S, Arcuri G, Condo I, Serio D, Incani O, et al. Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia. Hum Mol Genet. 2011;20:1253-61.
5. Pandolfo M, Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol. 2009;256 Suppl 1:9-17.
6. Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci. 2005;233:145-62. (Pubitemid 40812334)
7. Koeppen AH, Davis AN, Morral JA. The cerebellar component of Friedreich's ataxia. Acta Neuropathol. 2011;122:323-30.
8. Cavadini P, O'Neill HA, Benada O, Isaya G. Assembly and ironbinding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet. 2002;11:217-27. (Pubitemid 34173351)
9. Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal. 2010;13:651-90.
10. Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, Rotig A, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart. 2002;87:346-9. (Pubitemid 34270947)
11. Kemp K, Mallam E, Hares K, Witherick J, Scolding N, Wilkins A. Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts. PLoS One. 2011;6:e26098.
12. Kemp K, Gordon D, Wraith DC, Mallam E, Hartfield E, Uney J, et al. Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells. Neuropathol Appl Neurobiol 2010;37:166-78.
13. Kemp K, Gray E, Mallam E, Scolding N, Wilkins A. Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Stem Cell Rev 2010;6:548-59.
14. Mallam E, Kemp K, Wilkins A, Rice C, Scolding N. Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010;16:909-18.
15. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009;3:63-70.
16. Kemp K, Hares K, Mallam E, Heesom KJ, Scolding N, Wilkins A. Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival. J Neurochem. 2010;114:1569-80.
17. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33:337-49. (Pubitemid 34790245)
18. Wilkins A, Compston A. Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: roles and interactions of mitogen-activated protein kinase signalling pathways. J Neurochem. 2005;92:1487-96. (Pubitemid 40389217)
19. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet. 1997;6:1771-80. (Pubitemid 27460350)
20. Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303:1-12.
21. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, Monticelli A, et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry. 2004;75:1061-3. (Pubitemid 38869629)
22. Acquaviva F, Castaldo I, Filla A, Giacchetti M, Marmolino D, Monticelli A, et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum. 2008;7:360-5.
23. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006;2:551-8. (Pubitemid 44413238)
24. Pook MA, Al-Mahdawi S, Carroll CJ, Cossee M, Puccio H, Lawrence L, et al. Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics. 2001;3:185-93. (Pubitemid 33738404)
25. Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed). 2009;1:161-78.
26. Velasco-Sanchez D, Aracil A, Montero R, Mas A, Jimenez L, O'Callaghan M, et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum. 2011;10:1-8.
27. Sparaco M, Gaeta LM, Santorelli FM, Passarelli C, Tozzi G, Bertini E, et al. Friedreich's ataxia: oxidative stress and cytoskeletal abnormalities. J Neurol Sci. 2009;287:111-8.
28. Busi MV, Gomez-Casati DF. Exploring frataxin function. IUBMB Life 2012;64:56-63.
29. Armstrong JS, Khdour O, Hecht SM. Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question. FASEB J. 2010;24:2152-63.
30. Michiels C, Raes M, Toussaint O, Remacle J. Importance of Seglutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med. 1994;17:235-48.
31. Esposito LA, Kokoszka JE, Waymire KG, Cottrell B, MacGregor GR, Wallace DC. Mitochondrial oxidative stress in mice lacking the glutathione peroxidase-1 gene. Free Radic Biol Med. 2000;28:754-66. (Pubitemid 30171289)
32. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990;87:1620-4.
33. Schulz JB, Dehmer T, Schols L, Mende H, Hardt C, Vorgerd M, et al. Oxidative stress in patients with Friedreich ataxia. Neurology. 2000;55:1719-21.
34. Garcia-Gimenez JL, Gimeno A, Gonzalez-Cabo P, Dasi F, Bolinches-Amoros A, Molla B, et al. Differential expression of PGC-1alpha and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts. PLoS One. 2011;6:e20666.
35. Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich A, Rotig A, et al. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet. 2001;10:2061-7. (Pubitemid 32998818)
36. Seznec H, Simon D, Bouton C, Reutenauer L, Hertzog A, Golik P, et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet. 2005;14:463-74. (Pubitemid 40277462)
37. Irazusta V, Obis E, Moreno-Cermeno A, Cabiscol E, Ros J, Tamarit J. Yeast frataxin mutants display decreased superoxide dismutase activity crucial to promote protein oxidative damage. Free Radic Biol Med. 2010;48:411-20.
38. Paupe V, Dassa EP, Goncalves S, Auchere F, Lonn M, Holmgren A, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One. 2009;4: e4253.
39. Irazusta V, Cabiscol E, Reverter-Branchat G, Ros J, Tamarit J. Manganese is the link between frataxin and iron-sulfur deficiency in the yeastmodel of Friedreich ataxia. J Biol Chem. 2006;281:12227-32. (Pubitemid 43855305)
40. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997;411:373-7. (Pubitemid 27301488)
41. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, Taroni F, et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet. 1999;8:425-30. (Pubitemid 29097330)
42. Finocchietto PV, Franco MC, Holod S, Gonzalez AS, Converso DP, Antico Arciuch VG, et al. Mitochondrial nitric oxide synthase: a masterpiece of metabolic adaptation, cell growth, transformation, and death. Exp Biol Med (Maywood). 2009;234:1020-8.
43. Bayot A, Santos R, Camadro JM, Rustin P. Friedreich's ataxia: the vicious circle hypothesis revisited. BMC Med. 2011;9:112.
44. Napoli E, Taroni F, Cortopassi GA. Frataxin, iron-sulfur clusters, heme, ROS, and aging. Antioxid Redox Signal. 2006;8:506-16.
45. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10:381-91. (Pubitemid 30389307)
46. Goldberg JL, Barres BA. The relationship between neuronal survival and regeneration. Annu Rev Neurosci. 2000;23:579-612. (Pubitemid 30350055)
47. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59-71.
48. Klesse LJ, Parada LF. p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J Neurosci. 1998;18:10420-8. (Pubitemid 29016561)
49. Diem R, Meyer R, Weishaupt JH, Bahr M. Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-(alpha) rescues axotomized retinal ganglion cells from retrograde cell death in vivo. J Neurosci. 2001;21:2058-66. (Pubitemid 32221388)
50. Encinas M, Tansey MG, Tsui-Pierchala BA, Comella JX, Milbrandt J, Johnson Jr EM. c-Src is required for glial cell linederived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci. 2001;21:1464-72. (Pubitemid 32182188)
51. Crowder RJ, Freeman RS. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J Neurosci. 1998;18:2933-43. (Pubitemid 28163223)
52. Vaillant AR, Mazzoni I, Tudan C, Boudreau M, Kaplan DR, Miller FD. Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol. 1999;146:955-66. (Pubitemid 29430439)
53. Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, Mukai H, et al. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal. 2007;19:519-27. (Pubitemid 46107803)
54. Chen RW, Lu XC, Yao C, Liao Z, Jiang ZG,Wei H, et al. PAN-811 provides neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK. Neurosci Lett. 2007;422:64-7. (Pubitemid 47077577)
55. Yamagishi S, Matsumoto T, Yokomaku D, Hatanaka H, Shimoke K, Yamada M, et al. Comparison of inhibitory effects of brainderived neurotrophic factor and insulin-like growth factor on low potassium-induced apoptosis and activation of p38 MAPK and c-Jun in cultured cerebellar granule neurons. Brain Res Mol Brain Res. 2003;119:184-91. (Pubitemid 37415091)
56. Pandolfo M. Frataxin deficiency and mitochondrial dysfunction. Mitochondrion. 2002;2:87-93. (Pubitemid 35214600)